Investment Q&A

Q: Is this company profitable? Is it expensive? Do you see it as a hold, buy, or sell?
Thank you

Q: TLT has recently announced promising results for Rutherin, the molecule it is testing. E.g. "Enhanced Tumor Destruction: Radiation-activated Rutherrin® achieved a 100-fold increase in cancer cell kill versus radiation therapy alone." But it is tiny, with a multi-year path to final results and depends on raising further capital. How can an investor assess companies like this, and what is your opinion of TLT re getting an investment toe in the door?

Q: Has decent pipeline, growth and earnings. Appreciate your assessment. Thx

Q: What are the prospects of Crisper at their present price.
.Thanks . Thomas

Q: Thoughts on the quarter please?

Q: Seems like a decent recent report. Any reason for it's drop today? Thanks

Q: What did u think of their last quarter in light of the stock drop? Thank u

Q: Hello, KMB has come down 13% in the last 5 days because of the proposed merger with Kenvue. Is this an opportunity to buy? If so, should I wait a while for it to settle down some more? The big question is : is this going to end up like Bayer acquiring Monsanto and then facing a neverending stream of lawsuits? Thanks.

Q: how do you rank them to buy now 1 to 10 after the q3 reported. thanks

Q: thoughts on Q results for Well Health, well/t....looked great with record highs for Rev, etc....and Aidx reported supposedly good Q results...everything imo seemed positive....but again...stock seems to be stuck in neutral....U are the experts...what do you think on stock going forward....it has gradually bounced off lows at $4sh....but a long way from analyst targets of $7 - $9

Q: Hi Peter

Can you comment on Knight (GUD) $100MM US revolving bank credit facility released on Oct 31. How material is this in your view. And also would they be paying standby fees for having this facility. Appreciate your thoughts. Thank you

Q: hello 5i:
Recently, I asked the following question and you answered:

Q: hello 5i:
knowing you've been a fan of this company, from reading questions, can you comment on the fact that analyst earnings expectations have dropped from .23 (to year end 2025), 6 months ago, to currently .12. Has this changed your view of VHI?
thanks
Paul L
[Undo Upvote Icon] Undo Upvote 2
[Add to favourite Icon]
Asked by Paul on October 30, 2025
5i Research Answer:

According to Bloomberg, adjusted EPS goes from 12c estimated this year to 31c estimated in 2026. With $94M in cash and cash flow growing, we remain comfortable with the stock.

Perhaps I should have been a bit more specific. I could see their projected earnings via Fastgraphs, but...................VHI has, shall we say, a not stellar (dismal?) record of meeting or beating earnings. So what are projections really worth?As earnings have been revised downward so much in the last 6 months, what suggests they won't be revised downward at the same rate? If you have confidence that earnings will not be revised downward, you must know something. Could you share that something?
thanks
Paul L

Q: I would appreciate your perspective on the latest BMY earnings.

Q: hello 5i:
knowing you've been a fan of this company, from reading questions, can you comment on the fact that analyst earnings expectations have dropped from .23 (to year end 2025), 6 months ago, to currently .12. Has this changed your view of VHI?
thanks
Paul L

Q: CLPBY - COLOPLAST A S AMERICAN DEPOSITARY RECEIPTS SPONSORED

Hi guys

I have followed Coloplast (Danish company I believe) for a very long time as a good safe, reliable health care play, with an interesting way to play the aging demographic trend. I notice also that it is near a 52 week low and has trended downward generally the last 5 years. Probably not a great chart.

And realizing you don't generally follow too closely European stocks, do you have any thoughts on the company, its products, whether it has a moat around its products (seem to be a bit sticky once people start to use them), and its current valuation? A buyor better stocks in the health care products area?

Much thanks

Stuart

Q: Based on todays price, which would you favor? By a lot or a little bit?

Dennis

Q: I have a half position in ISRG (bought before latest Q). Would you go for adding to it (if it was your position to build on momentum) OVER buying LLY to get to 6% in US$ health? Looking for growth. I already have 3% in WELL

Q: What are your thoughts on BMY with the acquisitions and deals they've completed in 2024 and 2025?

What are your thoughts on Novocure as a hold over the next 3 years?

What are your thoughts on Summit Therapeutics as a small speculative position?

Q: Hello team, could you please give me your thoughts on XLV and IXJ.

Interested in how they compare and if you prefer one over the other. A good entry price would also be appreciated.

Thanks as always for your advice.
Paula

Q: A company called Rocket Doctor was talked about on market call the other day. Is it worth than investing in?